STUDY OBJECTIVE: To review experience with pneumococcal bacteremia at two Canadian tertiary care centers. DESIGN: Retrospective record review. SETTING: Two tertiary acute care teaching hospitals in Winnipeg, Manitoba. PATIENTS: Patients identified with pneumococcal bacteremia during an 8-year period. RESULTS: Hospital records were reviewed for 534 of 617 patients with pneumococcal bacteremia. The overall case fatality ratio was 70 (13%), varying from 3.2% in children to 43% in those older than 80 years. Twenty-seven (18%) hospitalized children and 68 (23%) adults required ICU admission. Duration of hospitalization was 14.9 +/- 24.9 and 11.0 +/- 19.1 days for children at the two institutions and 22.5 +/- 37.6 days and 38 +/- 93 days for adults. For the 217 viable pneumococcal strains studied, 89% were serotypes included in the present 23-valent vaccine. Documentation of prior vaccination was present for only 9 (1.7%) patients, although 281 (89%) adults and 99 (45%) children met criteria for vaccination. CONCLUSIONS: Mortality in our population is similar to previous reports. More widespread pneumococcal vaccination in eligible populations may not only decrease mortality, but may also provide savings through decreased hospital admission and need for intensive care.
STUDY OBJECTIVE: To review experience with pneumococcal bacteremia at two Canadian tertiary care centers. DESIGN: Retrospective record review. SETTING: Two tertiary acute care teaching hospitals in Winnipeg, Manitoba. PATIENTS: Patients identified with pneumococcal bacteremia during an 8-year period. RESULTS: Hospital records were reviewed for 534 of 617 patients with pneumococcal bacteremia. The overall case fatality ratio was 70 (13%), varying from 3.2% in children to 43% in those older than 80 years. Twenty-seven (18%) hospitalized children and 68 (23%) adults required ICU admission. Duration of hospitalization was 14.9 +/- 24.9 and 11.0 +/- 19.1 days for children at the two institutions and 22.5 +/- 37.6 days and 38 +/- 93 days for adults. For the 217 viable pneumococcal strains studied, 89% were serotypes included in the present 23-valent vaccine. Documentation of prior vaccination was present for only 9 (1.7%) patients, although 281 (89%) adults and 99 (45%) children met criteria for vaccination. CONCLUSIONS: Mortality in our population is similar to previous reports. More widespread pneumococcal vaccination in eligible populations may not only decrease mortality, but may also provide savings through decreased hospital admission and need for intensive care.
Authors: Daniel M Weinberger; Zitta B Harboe; Elisabeth A M Sanders; Moses Ndiritu; Keith P Klugman; Simon Rückinger; Ron Dagan; Richard Adegbola; Felicity Cutts; Hope L Johnson; Katherine L O'Brien; J Anthony Scott; Marc Lipsitch Journal: Clin Infect Dis Date: 2010-09-15 Impact factor: 9.079
Authors: G C Beck; N Rafat; P Brinkkoetter; C Hanusch; J Schulte; M Haak; K van Ackern; F J van der Woude; B A Yard Journal: Clin Exp Immunol Date: 2006-03 Impact factor: 4.330